Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Ace­lyrin start­ed trad­ing on the Nas­daq Fri­day morn­ing in one of the largest biotech ini­tial pub­lic of­fer­ings in re­cent mem­o­ry, with $540 mil­lion in gross pro­ceeds and po­ten­tial­ly $621 mil­lion if un­der­writ­ers ex­er­cise their 30-day op­tion to buy more shares.

End­points News di­aled up Shao-Lee Lin, the Cal­i­for­nia drug de­vel­op­er’s CEO, on Thurs­day night in ad­vance of Ace­lyrin’s $SLRN list­ing, which priced at $18, the high end of its pro­posed range. In a sign of mar­ket ap­petite for the late-stage im­munol­o­gy biotech, Ace­lyrin upped the size of its of­fer­ing twice this week in the lead-up to its de­but, grow­ing from 20.6 mil­lion to 26.5 mil­lion shares be­fore a fi­nal tal­ly of 30 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER